3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Large B-Cell, Diffuse
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Burkitt Lymphoma
5
Prostatic Neoplasms
4
Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Ovarian Neoplasms
3
Lymphoma, Follicular
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Metastatic Castration-resistant Prostate Cancer
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lymphoma
2
Hodgkin Disease
2
Endometrial Neoplasms
2
Down Syndrome
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Myasthenia Gravis
1
Lymphoma, T-Cell, Peripheral
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Adrenal Insufficiency
1
Interventions
rozanolixizumab
5
ravulizumab
5
zilucoplan
4
fludarabine
3
Cyclophosphamide
3
telitacicept
2
inebilizumab
2
talquetamab
1
remibrutinib
1
iptacopan
1
efgartigimod alfa
1
Therapeutics
1
Prednisone
1
Prednisolone
1
Plasma Exchange
1
Immunoglobulins, Intravenous
1
HBM9161
1
Cladribine
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
Prednisolone
×
90 days
×
Clear all
NCT07221838
2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4
Recruiting
75 enrolled